HSS Journal: The Musculoskeletal Journal of Hospital for Special Surgery , 21(3), 115
No Current UK Marketing Authorisation Identified No current UK marketing authorisation for a BPC-157 plus TB-500 combination, BPC-157 or TB-500 was identified in the official sources reviewed for this article
Heres the critical point: as we age, our natural levels of NAD+ decline significantly, by as much as 50% by the time we reach middle age
much lower at community doses Vomiting up to 36% at high doses Diarrhea 23-26% Constipation 17-19% Fatigue 11-13% Pancreatitis risk trials flagged severe abdominal pain for discontinuation and evaluation Gallbladder issues rapid weight loss increases gallstone risk Thyroid C-cell tumors same boxed warning as semaglutide (animal studies) GI side effects were more intense than semaglutide in trial data due to the dual mechanism
No single-receptor or even dual-receptor agonist can replicate this combination, which is why retatrutide produced weight loss numbers that surpassed both Ozempic and tirzepatide in clinical comparisons
~ AlphaMD For decades, testosterone replacement therapy (TRT) was primarily seen as a tool to boost energy, sex drive, and muscle mass in men with low testosterone levels
